scholarly journals Fat Deposition in Broilers: Effect of Dietary Energy to Protein Balance, and Early Life Caloric Restriction on Productive Performance and Abdominal Fat Pad Size

1977 ◽  
Vol 56 (2) ◽  
pp. 638-646 ◽  
Author(s):  
L. Griffiths ◽  
S. Leeson ◽  
J.D. Summers
Keyword(s):  
Caloric Restriction ◽  
Early Life ◽  
Abdominal Fat ◽  
Fat Deposition ◽  
Dietary Energy ◽  
Productive Performance ◽  
Fat Pad ◽  
Protein Balance

scholarly journals Effect of phytase dose on productive performance and bone status of layers fed with graded levels of digestible lysine

2018 ◽  
Vol 5 (3) ◽  
Author(s):  
Ingrid Yolani Martinez Rojas ◽  
Carlos López Coello ◽  
Ernesto Ávila González ◽  
J. Arce Menocal ◽  
G. A. Gomes
Keyword(s):  
Body Weight ◽  
Egg Production ◽  
Breaking Strength ◽  
Abdominal Fat ◽  
Fat Deposition ◽  
Egg Mass ◽  
Productive Performance ◽  
Bone Status ◽  
Bone Ash ◽  
Abdominal Fat Deposition

Exogenous phytase could influence dietary protein availability by variation in using dose. The objective of the present study was to determine if incremental dosing of an evolved E.coli 6-phytase would lead to improvements in lysine availability through evaluating performance and bone status in Bovans White layers. A total of 182 layers were placed in individual cages and distributed to 13 treatments: a 3×4 factorial arrangement with three levels of digestible lysine (dLys - 0.67, 0.77, and 0.87 %) and four doses of phytase (0, 300, 1 200, and 4 800 FTU/kg) in 0.12 % available P (avP) diets. Additionally, one phytase-free control treatment was included with 0.25 % avP and 0.87 % dLys. Productive parameters were recorded for 25 weeks, from 39 week-old. At the end, abdominal fat deposition and the tibia were sampled; in bone was determined breaking strength and bone ash. Layers fed 1 200 FTU/kg phytase increased egg production percentage (F3,169 = 2.01, p = 0.019), abdominal fat deposition (F3,169 = 2.52, p = 0.059), bone breaking strength (F3,169 = 4.29, p = 0.006) and bone ash weight (F3,169 = 3.62, p = 0.015) compared with non-phytase inclusion. Furthermore, 1 200 FTU/kg phytase decreased incidence of broken eggs and soft-shell eggs (F3,169 = 2.9, p = 0.037). Phytase and dLys levels influenced egg mass and bone ash concentration (F12,169 = 1.86, p = 0.043). FCR and body weight loss was reduced with phytase inclusion (respectively: F12,169 = 2.43, p = 0.045, and F12,169 = 2.24, p = 0.001). Phytase-free control diet increased egg weight (F12,169 = 3.70, p < 0.068), but gave greater BW loss (F12,169 = 17.79, p < 0.001), less abdominal fat content (F12,169 = 5.85, p < 0.017), and no effect on other variables (p > 0.07). In conclusion, 1 200 FTU/kg of phytase improved productive performance and preserved body weight and bone status, without equivalence of phytase inclusion for dLys level, even with higher doses.Figure A. Response of egg marketable mass

Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: Relationship with abdominal fat deposition

2007 ◽  
Vol 17 (4) ◽  
pp. 294-302 ◽  
Author(s):  
Alexis E. Malavazos ◽  
Massimiliano M. Corsi ◽  
Federica Ermetici ◽  
Calin Coman ◽  
Francesco Sardanelli ◽  
...  
Keyword(s):  
Proinflammatory Cytokines ◽  
Abdominal Fat ◽  
Fat Deposition ◽  
Cardiac Abnormalities ◽  
Abdominal Fat Deposition

scholarly journals 935. Effect of Tesamorelin in People with HIV with and without Dorsocervical Fat: Post Hoc Analysis of Phase III Double Blind Placebo Control Trial

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S500-S501
Author(s):  
Farah Rahman ◽  
Marilyn de Chantal ◽  
Pedro Mesquita ◽  
Judith A Aberg
Keyword(s):  
Growth Hormone ◽  
Abdominal Fat ◽  
Fat Deposition ◽  
Phase Iii ◽  
Placebo Control ◽  
People Living With Hiv ◽  
Anthropometric Parameters ◽  
Double Blind ◽  
Post Hoc Analysis ◽  
Post Hoc

Abstract Background Lipohypertrophy is defined as excess fat deposition in abdominal defined as visceral adipose tissue (VAT) as well as in the dorsocervical region, breasts, trunk, and along with possible fat deposition in liver, muscle, myocardium and epicardium. Multiple factors have been described as contributing to lipohypertrophy in people living with HIV (PLWH), including patient characteristics, antiretroviral therapy (ART) and also impaired growth hormone (GH) secretion. Tesamorelin, a synthetic form of growth-hormone-releasing hormone (GHRH), is indicated for reduction of excess abdominal fat in PLWH with lipodystrophy Methods Post-hoc analysis was done on phase 3 randomized, double-blind, multicenter trials. Patients were eligible if between 18 and 65 years of age, had confirmed HIV infection, had evidence of excess abdominal fat accumulation and on stable ART regimen for 8 weeks or more. Participants were randomized to receive tesamorelin 2 mg daily or placebo daily for 26 weeks. Only tesamorelin responders, defined as patients with at least 8% decrease in VAT and who were adherent to the medication, were used for this analysis. Results are reported for patients with and without dorsocervical (DC) fat deposition. Results Demographic characteristics of responders at week 26 are shown according to presence or absence of DC fat (Table 1). At week 26, on average, the patients with DC fat deposition had higher BMI and waist circumference (WC) than the group without DC fat. Most patients in both groups had lipoatrophy. Metabolic and anthropometric parameters were measured at week 26 in patients with and without DC fat (Table 2). There was a decrease in VAT and also an improvement in their WC at week 26 in both groups. Table 1: Baseline Characteristics of Tesamorelin Responder Subjects at Week 26, by Dorsocervical Status Table 2: Change in Abdominal Adiposity, Insulin-Like Growth Factor-1 Levels, and Metabolic Parameters Between Baseline and Week 26 Among Tesamorelin Responders Conclusion This data demonstrates that tesamorelin is effective at reducing VAT in both patients with and without DC fat. The medication was well tolerated without significant changes to metabolic based measurements. Treatment of excessive VAT with tesamorelin has seemingly positive results in fat reduction in patients with or without DC fat deposition and our study contributes to the growing literature. Disclosures Marilyn de Chantal, PhD, Theratechnologies Inc (Employee) Pedro Mesquita, PhD, Theratechnologies, Inc. (Employee) Judith A. Aberg, MD, Theratechnology (Consultant)

Sign in / Sign up

Export Citation Format

Share Document